A Phase 1/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Bavdegalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ARDENT
- Sponsors Arvinas
- 29 Jan 2025 Planned End Date changed from 30 Nov 2024 to 27 Jan 2025.
- 29 Jan 2025 Planned primary completion date changed from 31 Mar 2024 to 27 Jan 2025.
- 10 Nov 2023 Status changed from recruiting to active, no longer recruiting.